Overview
Liver fibrosis screening is possible at the asymptomatic stage through a healthcare management strategy currently recommended for patients with risk factors for chronic liver disease. It is based on a sequential strategy involving a 1st-line test, fibrosis score calculation (FIB-4).
Given this opportunity to identify advanced fibrosis in asymptomatic patients, the project aims to set up this screening program in the Grenoble area with Biogroup Laboratories, in collaboration with the Hepato-gastroenterology department (HGE) of Grenoble University Hospital. The aim of this study is to evaluate the success of sequential screening using FIB-4, followed by a specialized fibrosis test for the diagnosis of advanced hepatic fibrosis
Eligibility
Inclusion Criteria:
- Patients between 18 and 70 years of age
- FIB-4 2.67
- Patients covered by Health Insurance System
Exclusion Criteria:
- Prescription triggering FIB-4 emanate from a hepatogastroenterologist or oncologist
- Conditions associated with high risk false-positive FIB-4: ASAT or ALAT \> 300 IU/L, platelets \<50 G/L or \>500 G/L.
- Patient refusing to participate
- Subjects under guardianship or deprived of liberty
